Resources
Browse our materials
for additional information

Contact us

The following is a searchable and filterable list of our news posts, press releases, white papers, articles, scientific posters, and much more.
If you can’t find something, please let us know and we’ll reach out to you as soon as we can.

Filtered (14)
Filters
Search:
Filter your resources:
Show (14)
Cancel

  • Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach

     J Cancer Res Clin Oncol 150, 367 (2024). https://doi.org/10.1007/s00432-024-05901-4
    Open resource

  • A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

    Schell, MJ. Nat Commun. 2016;7:11743
    Open resource

  • Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer

    Malgerud, L. et al. Mol Oncol. 2017;11(10):1413-1429
    Open resource

  • Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide

    Hirotsu, Y. et al. Int J Mol Sci. 2020;21(11):3895
    Open resource

  • Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study

    Jaeger, BAS. Geburtshilfe Frauenheilkd. 2023;83(9):1138-1147
    Open resource

  • Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)

    Jackson, D.B. et al. Pharmaceutics 2023, 15(6), 1673
    Open resource

  • Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide

    Mustea, A. et al. Cancers 2023, 15(7), 2023
    Open resource

  • Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms

    Brock, S. et al. Front. Mol. Med. 2023, 2:1035290. https://doi.org/10.3389/fmmed.2022.1035290
    Open resource

  • Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports

    Soldatos, T. G. et al. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):540-555. doi: 10.1002/psp4.12765
    Open resource

  • Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics

    Heydt, C. et al. J. Mol. Pathol. 2022, 3(1), 53-67; https://doi.org/10.3390/jmp3010006
    Open resource

  • Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

    Kim, S. et al. Clin Transl Sci. 2022 Jun;15(6):1430-1438. doi: 10.1111/cts.13254
    Open resource

  • The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease

    Brock, S. et al. Front. Mol. Med. 2022, 2:1035215. https://doi.org/10.3389/fmmed.2022.1035215
    Open resource

  • Target adverse event profiles for predictive safety in the postmarket setting

    Peter Schotland, Rebecca Racz, David B. Jackson, Theodoros G. Soldatos, Robert Levin, David G. Strauss and Keith Burkhart. Clinical Pharmacology & Therapeutics Volume 109, Issue 5, Pages: 1159-1362 (May 2021)
    Open resource

  • A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development

    Kim, S. et al. Clin Transl Sci . 2022 Apr;15(4):1003-1013. doi: 10.1111/cts.13219
    Open resource
GDPR Cookie Consent with Real Cookie Banner